Tags

Type your tag names separated by a space and hit enter

Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
Chem Pharm Bull (Tokyo). 2019; 67(6):540-545.CP

Abstract

Fixed-dose combination (FDC) medicines containing two or more active pharmaceutical ingredients (APIs) in a single dosage form have been reported to improve patient adherence to a greater extent than single dosages of individual components (ICs). Orally disintegrating tablets (ODTs) are easier to swallow than conventional tablets. The aim of this study was to elucidate the clinical pharmaceutical characteristics of taking a FDC-ODT and two IC-ODTs. We prepared three ODTs containing mitiglinide, voglibose, and mitiglinide/voglibose and three corresponding placebo ODTs and performed 2 independent clinical trials with 13 healthy subjects (mean age, 23.4 ± 1.6 years). One trial evaluated the ease of taking tablets and the amount of water required for taking the tablets; placebo ODTs were used in order to avoid administering APIs. The other trial evaluated the bitterness, sweetness and overall palatability of ODTs containing APIs during disintegration and after spitting out. Ease and taste were evaluated using both a visual analog scale (VAS) and a verbal rating scale (VRS). The results of the VAS and VRS evaluation indicated that FDC-ODT could ease tablet intake unlike IC-ODTs. In addition, FDC-ODT reduced the amount of water required for tablet intake in contrast to IC-ODTs. Taste evaluation results did not reveal any difference between FDC-ODT and IC-ODTs, except for the sweetness score after spitting out. In conclusion, FDC-ODT is easy to take and can help improve patient adherence.

Authors+Show Affiliations

Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences University of Shizuoka.Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences University of Shizuoka.Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine.Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences University of Shizuoka.Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences University of Shizuoka.Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine.Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine. Center for Clinical Research, Hamamatsu University Hospital.Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine.Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine.Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences University of Shizuoka.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31155559

Citation

Sotoyama, Mai, et al. "Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets." Chemical & Pharmaceutical Bulletin, vol. 67, no. 6, 2019, pp. 540-545.
Sotoyama M, Uchida S, Kamiya C, et al. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets. Chem Pharm Bull. 2019;67(6):540-545.
Sotoyama, M., Uchida, S., Kamiya, C., Tanaka, S., Kashiwagura, Y., Hakamata, A., Odagiri, K., Inui, N., Watanabe, H., & Namiki, N. (2019). Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets. Chemical & Pharmaceutical Bulletin, 67(6), 540-545. https://doi.org/10.1248/cpb.c18-00902
Sotoyama M, et al. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets. Chem Pharm Bull. 2019;67(6):540-545. PubMed PMID: 31155559.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets. AU - Sotoyama,Mai, AU - Uchida,Shinya, AU - Kamiya,Chiaki, AU - Tanaka,Shimako, AU - Kashiwagura,Yasuharu, AU - Hakamata,Akio, AU - Odagiri,Keiichi, AU - Inui,Naoki, AU - Watanabe,Hiroshi, AU - Namiki,Noriyuki, PY - 2019/6/4/entrez PY - 2019/6/4/pubmed PY - 2019/6/25/medline KW - fixed-dose combination KW - mitiglinide KW - orally disintegrating tablet KW - palatability KW - voglibose SP - 540 EP - 545 JF - Chemical & pharmaceutical bulletin JO - Chem. Pharm. Bull. VL - 67 IS - 6 N2 - Fixed-dose combination (FDC) medicines containing two or more active pharmaceutical ingredients (APIs) in a single dosage form have been reported to improve patient adherence to a greater extent than single dosages of individual components (ICs). Orally disintegrating tablets (ODTs) are easier to swallow than conventional tablets. The aim of this study was to elucidate the clinical pharmaceutical characteristics of taking a FDC-ODT and two IC-ODTs. We prepared three ODTs containing mitiglinide, voglibose, and mitiglinide/voglibose and three corresponding placebo ODTs and performed 2 independent clinical trials with 13 healthy subjects (mean age, 23.4 ± 1.6 years). One trial evaluated the ease of taking tablets and the amount of water required for taking the tablets; placebo ODTs were used in order to avoid administering APIs. The other trial evaluated the bitterness, sweetness and overall palatability of ODTs containing APIs during disintegration and after spitting out. Ease and taste were evaluated using both a visual analog scale (VAS) and a verbal rating scale (VRS). The results of the VAS and VRS evaluation indicated that FDC-ODT could ease tablet intake unlike IC-ODTs. In addition, FDC-ODT reduced the amount of water required for tablet intake in contrast to IC-ODTs. Taste evaluation results did not reveal any difference between FDC-ODT and IC-ODTs, except for the sweetness score after spitting out. In conclusion, FDC-ODT is easy to take and can help improve patient adherence. SN - 1347-5223 UR - https://www.unboundmedicine.com/medline/citation/31155559/Ease_of_Taking_and_Palatability_of_Fixed_Dose_Orally_Disintegrating_Mitiglinide/Voglibose_Tablets_ L2 - https://dx.doi.org/10.1248/cpb.c18-00902 DB - PRIME DP - Unbound Medicine ER -